Impact of Glucoraphanin-Mediated Activation of Nrf2 on Non-Alcoholic Fatty Liver Disease with a Focus on Mitochondrial Dysfunction.
Nrf2
chronic inflammation
glucoraphanin
insulin resistance
mitochondrial dysfunction
nonalcoholic fatty liver disease (NAFLD)
sulforaphane
Journal
International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791
Informations de publication
Date de publication:
25 Nov 2019
25 Nov 2019
Historique:
received:
31
10
2019
revised:
19
11
2019
accepted:
23
11
2019
entrez:
29
11
2019
pubmed:
30
11
2019
medline:
6
5
2020
Statut:
epublish
Résumé
Non-alcoholic fatty liver disease (NAFLD) is a common disease in Western nations and ranges in severity from steatosis to steatohepatitis (NASH). NAFLD is a genetic-environmental-metabolic stress-related disease of unclear pathogenesis. NAFLD is triggered by caloric overconsumption and physical inactivity, which lead to insulin resistance and oxidative stress. A growing body of evidence indicates that mitochondrial dysfunction plays a critical role in the pathogenesis of NAFLD. Mitochondrial dysfunction not only promotes fat accumulation, but also leads to generation of reactive oxygen species (ROS) and lipid peroxidation, resulting in oxidative stress in hepatocytes. Nuclear factor erythroid 2-related factor 2 (Nrf2) is an important modulator of antioxidant signaling that serves as a primary cellular defense against the cytotoxic effects of oxidative stress. The pharmacological induction of Nrf2 ameliorates obesity-associated insulin resistance and NAFLD in a mouse model. Sulforaphane and its precursor glucoraphanin are derived from broccoli sprouts and are the most potent natural Nrf2 inducers-they may protect mitochondrial function, thus suppressing the development of NASH. In this review, we briefly describe the role of mitochondrial dysfunction in the pathogenesis of NASH and the effects of glucoraphanin on its development.
Identifiants
pubmed: 31775341
pii: ijms20235920
doi: 10.3390/ijms20235920
pmc: PMC6929181
pii:
doi:
Substances chimiques
Glucosinolates
0
Imidoesters
0
NF-E2-Related Factor 2
0
Oximes
0
Sulfoxides
0
glucoraphanin
Q86A197713
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Japan Society for the Promotion of Science KAKENHI (T.O.)
ID : 15K12698, 16H03035
Organisme : Japan Society for the Promotion of Science KAKENHI (N.N.)
ID : 15K00813
Déclaration de conflit d'intérêts
The authors declare no conflict of interest.
Références
Diabetes Obes Metab. 2010 Oct;12 Suppl 2:83-92
pubmed: 21029304
Hepatology. 2004 May;39(5):1286-96
pubmed: 15122757
Cell Metab. 2018 Jan 9;27(1):22-41
pubmed: 28867301
J Clin Endocrinol Metab. 2015 May;100(5):E821-5
pubmed: 25763607
Proc Natl Acad Sci U S A. 2011 Sep 27;108(39):16381-5
pubmed: 21930939
J Pediatr. 2019 Apr;207:64-70
pubmed: 30559024
Hepatology. 2014 May;59(5):2034-42
pubmed: 24115204
Cell Metab. 2015 May 5;21(5):739-46
pubmed: 25955209
Nutr Metab Cardiovasc Dis. 2019 Feb;29(2):191-200
pubmed: 30573307
Dig Dis Sci. 2014 Dec;59(12):2967-74
pubmed: 25069572
Nutrition. 2015 Sep;31(9):1175-8
pubmed: 26004191
Carcinogenesis. 2012 Jan;33(1):101-7
pubmed: 22045030
Front Immunol. 2014 Sep 26;5:470
pubmed: 25309549
Cell Metab. 2014 Dec 2;20(6):939-52
pubmed: 25448702
Sci Rep. 2017 Oct 26;7(1):14130
pubmed: 29074861
Hepatol Commun. 2018 Oct 30;2(12):1425-1439
pubmed: 30556032
Braz J Med Biol Res. 2006 Feb;39(2):189-94
pubmed: 16470305
Clin Liver Dis. 2009 Nov;13(4):511-31
pubmed: 19818302
J Clin Invest. 2007 Jan;117(1):175-84
pubmed: 17200717
Pflugers Arch. 2017 Apr;469(3-4):385-396
pubmed: 28233125
N Engl J Med. 2002 Apr 18;346(16):1221-31
pubmed: 11961152
Hepatology. 2007 Nov;46(5):1392-403
pubmed: 17929294
Liver Int. 2018 Feb;38 Suppl 1:47-51
pubmed: 29427488
Hepatology. 2018 Jul;68(1):349-360
pubmed: 29222917
Cell Metab. 2007 Jun;5(6):415-25
pubmed: 17550777
Nat Rev Endocrinol. 2012 Dec;8(12):709-16
pubmed: 22847239
Annu Rev Biochem. 1980;49:395-420
pubmed: 6157353
Lipids Health Dis. 2016 Sep 17;15(1):159
pubmed: 27640119
J Clin Invest. 2017 Jun 30;127(7):2855-2867
pubmed: 28628040
Gastroenterology. 2015 Aug;149(2):367-78.e5; quiz e14-5
pubmed: 25865049
Hepatology. 2010 Nov;52(5):1836-46
pubmed: 21038418
Annu Rev Physiol. 2016;78:23-44
pubmed: 26474213
Gastroenterology. 1998 Apr;114(4):842-5
pubmed: 9547102
Front Endocrinol (Lausanne). 2013 Jan 08;3:181
pubmed: 23316186
J Biomed Res. 2013 Jan;27(1):1-13
pubmed: 23554788
Nat Rev Immunol. 2003 Jan;3(1):23-35
pubmed: 12511873
Hepatology. 2004 Dec;40(6):1387-95
pubmed: 15565570
World J Gastrointest Pathophysiol. 2016 May 15;7(2):211-7
pubmed: 27190693
Toxicol Appl Pharmacol. 2010 Jun 15;245(3):326-34
pubmed: 20350562
J Neurochem. 2015 Dec;135(5):932-42
pubmed: 26365487
Hepatology. 1998 Jun;27(6):1463-6
pubmed: 9620314
Proc Natl Acad Sci U S A. 2014 Jun 17;111(24):8913-8
pubmed: 24927523
Trends Cell Biol. 2016 Mar;26(3):190-201
pubmed: 26616193
Free Radic Biol Med. 2012 May 1;52(9):1708-15
pubmed: 22370093
Redox Biol. 2017 Apr;11:103-110
pubmed: 27889639
Biomolecules. 2015 Jul 21;5(3):1563-79
pubmed: 26197341
Mol Med Rep. 2013 Dec;8(6):1611-6
pubmed: 24100795
Science. 1993 Jan 1;259(5091):87-91
pubmed: 7678183
Biochim Biophys Acta. 2015 Apr;1850(4):794-801
pubmed: 25484314
Am J Clin Nutr. 2013 Sep;98(3):712-22
pubmed: 23964055
Best Pract Res Clin Gastroenterol. 2014 Aug;28(4):637-53
pubmed: 25194181
J Hepatol. 2015 Jul;63(1):164-73
pubmed: 25703085
Biol Pharm Bull. 2018 Jul 1;41(7):985-993
pubmed: 29709897
Hepatology. 2012 Mar;55(3):781-9
pubmed: 22105854
Hepatology. 2003 Oct;38(4):999-1007
pubmed: 14512887
J Mol Endocrinol. 2015 Dec;55(3):169-81
pubmed: 26464382
Integr Med (Encinitas). 2014 Aug;13(4):35-43
pubmed: 26770107
Diabetes. 2017 May;66(5):1222-1236
pubmed: 28209760
Diabetes Care. 2010 Oct;33(10):2277-84
pubmed: 20876708
Nat Rev Gastroenterol Hepatol. 2010 May;7(5):251-64
pubmed: 20368739
Science. 2011 Jun 24;332(6037):1519-23
pubmed: 21700865
Cell Metab. 2007 Jun;5(6):426-37
pubmed: 17550778
Mol Cell Proteomics. 2018 Dec;17(12):2371-2386
pubmed: 30171159
Mitochondrion. 2008 Dec;8(5-6):367-76
pubmed: 18765303
Free Radic Biol Med. 2015 Nov;88(Pt B):179-188
pubmed: 25975984
Oncotarget. 2018 Feb 27;9(19):15047-15060
pubmed: 29599925
Br J Dermatol. 2013 Jul;169 Suppl 2:1-8
pubmed: 23786614
Hepatology. 2014 Jan;59(1):130-42
pubmed: 23832548
Transl Res. 2014 Oct;164(4):312-22
pubmed: 25028077
Clin Liver Dis. 2016 May;20(2):293-312
pubmed: 27063270
Free Radic Biol Med. 2009 Nov 1;47(9):1304-9
pubmed: 19666107
Curr Opin Toxicol. 2016 Dec;1:80-91
pubmed: 28066829
World J Gastroenterol. 2015 Nov 21;21(43):12457-67
pubmed: 26604653
Diabetes Care. 2010 Oct;33(10):2156-63
pubmed: 20664019
Mitochondrion. 2006 Feb;6(1):1-28
pubmed: 16406828
Oxid Med Cell Longev. 2013;2013:184598
pubmed: 24194976
Gastroenterology. 2012 Jun;142(7):1592-609
pubmed: 22656328
J Hepatol. 2009 Jul;51(1):212-23
pubmed: 19447517
PLoS One. 2012;7(6):e38322
pubmed: 22719876
EBioMedicine. 2017 Jun;20:137-149
pubmed: 28579299
Diabetes. 2002 Jun;51(6):1722-8
pubmed: 12031958
Gastroenterology. 2018 Sep;155(3):629-647
pubmed: 30012333
Ann Hepatol. 2014 Sep-Oct;13(5):489-95
pubmed: 25152980
Trends Mol Med. 2004 Nov;10(11):549-57
pubmed: 15519281
Oxid Med Cell Longev. 2017;2017:3839756
pubmed: 28386307
Eur J Pharmacol. 2009 Oct 12;620(1-3):138-44
pubmed: 19698707
Aliment Pharmacol Ther. 2008 Mar 1;27(5):412-21
pubmed: 18081738
J Hepatol. 2017 Jul;67(1):128-136
pubmed: 28235613
Cell Metab. 2008 Jun;7(6):496-507
pubmed: 18522831
Diabetologia. 2011 Apr;54(4):922-34
pubmed: 21161163
Ann Hepatol. 2017 Oct 16;16(6):909-915
pubmed: 29055919
PLoS One. 2011;6(9):e24084
pubmed: 21909411
Cold Spring Harb Symp Quant Biol. 2002;67:491-8
pubmed: 12858575
Hepatology. 2016 Mar;63(3):764-75
pubmed: 26600078
J Hepatol. 2005 Jun;42(6):928-40
pubmed: 15885365
Hepatology. 2014 Feb;59(2):713-23
pubmed: 23929732